NanoVibronix, Inc. announced it has signed an International Marketing, Sales and Clinical Management Agreement with Medtech Solutions Group (MTSG). The agreement allows MTSG to commercialize UroShield® and PainShield® throughout Europe, excluding the United Kingdom, Ireland, Malta and Turkey; Asia Pacific, Africa, Central and South America and certain parts of the Middle East. This agreement expands the Company's addressable market by tens of millions of dollars and should enable availability of its products to new populations of patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7755 USD | -0.84% | +8.46% | -32.57% |
1st Jan change | Capi. | |
---|---|---|
-32.57% | 2.16M | |
-4.90% | 182B | |
-1.36% | 104B | |
-7.64% | 45.58B | |
+9.30% | 46.44B | |
+9.63% | 44.34B | |
+13.63% | 29.44B | |
+20.29% | 26.8B | |
-7.12% | 23.82B | |
+4.03% | 22.61B |
- Stock Market
- Equities
- NAOV Stock
- News NanoVibronix, Inc.
- NanoVibronix, Inc. Signs an International Marketing, Sales and Clinical Management Agreement with Medtech Solutions Group